For the second time in two years, an Alzheimer's drug has shown meaningful slowing of cognitive decline in a large clinical trial. The latest results — from a Phase 3 study involving over 1,700 patients — show a 35% reduction in decline over 18 months compared to placebo. It's not a cure. But for families watching loved ones fade, it's something real.
How It Works
Like lecanemab (Leqembi) before it, this new treatment targets amyloid plaques in the brain — the protein clumps that have been ...
